Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.